Creathor’s therapeutic options

How Creathor’s new fund should get the VC into therapeutics

Creathor Venture expects its fourth and largest fund will allow the pan-European VC to invest in therapeutics companies previously considered too capital-intensive.

Karlheinz Schmelig told BioCentury Creathor Venture IV, a mixed IT and life sciences fund, is targeting €120 million ($132.6 million),

Read the full 418 word article

User Sign In